Fortress Biotech Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
Key Highlights
- ➤Q3 net revenue $19.2 million, up approximately 9% year over year
- ➤Fortress repaid remaining $15.0 million Oaktree principal, eliminating parent-level debt
- ➤Q3 net loss attributable to common stockholders reached $7.9 million, or $0.23 per share
- ➤Journey Medical’s Emrosi generated approximately 40,000 prescriptions in Q3 2026
- ➤Crystalys Therapeutics raised $130 million Series B financing for dotinurad development
Expert Statements
Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer of Fortress Biotech
“The third quarter of 2026 reflected continued execution across our diversified portfolio.”
Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer of Fortress Biotech
“In September, we repaid in full our credit facility with Oaktree and we also recently announced the in-licensing of FB-607, a novel combination therapy to treat the symptoms of irritable bowel syndrome with diarrhea (“IBS-D”).”
Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer of Fortress Biotech
“FB-607 is currently being studied in a randomized, placebo-controlled, Phase 2 trial for IBS-D and we expect to release top-line data in the second half of 2027.”
Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer of Fortress Biotech
“Journey Medical continues to build momentum with Emrosi(®), with approximately 40,000 in total prescriptions for the third quarter of 2026, supported by continued improvement in the mix of prescriptions reimbursed by health plans.”
Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer of Fortress Biotech
“Additionally, in September, anselamimab (formerly CAEL-101) was approved in Japan for the treatment of systemic kappa light chain amyloidosis.”
Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer of Fortress Biotech
“With our growing royalty income from ZYCUBO(®) and UNLOXCYT™, and multiple potential catalysts across our partnered programs, we believe Fortress is well positioned to continue driving long-term value for our shareholders.”
Total net revenue increased approximately 9% to $19.2 million for the third quarter of 2026 compared to the third quarter of 2025
Fortress repaid its credit facility in full in September 2026
Get started
Create a free account to read the full story.